International journal of clinical oncology
Reassessing prognostic markers in metastatic renal cell carcinoma in the era of immune checkpoint inhibitors: the enduring value of body composition, nutritional, and inflammatory indices.
Norihiko Tsuchiya, Sei Naito, Hiroki Fukuhara, Hayato Nishida, Mayu Yagi, Yuki Takai, Atsushi Yamagishi, Takafumi Narisawa, Shinta Suenaga
Published: 202610.1007/s10147-025-02855-6
Abstract
BACKGROUND: Immune checkpoint inhibitors (ICIs) are now the standard first-line treatment for metastatic renal cell carcinoma (mRCC), yet many risk factors identified during the tyrosine kinase inhibitor era remain unvalidated in current practice. Th…
Preview only. Read the full abstract at the source